These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28750660)

  • 21. A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing.
    Cybulska P; Stewart JM; Sayad A; Virtanen C; Shaw PA; Clarke B; Stickle N; Bernardini MQ; Neel BG
    Am J Pathol; 2018 May; 188(5):1120-1131. PubMed ID: 29458007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
    Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.
    Li L; Bai H; Yang J; Cao D; Shen K
    Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
    Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
    Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data.
    Ha G; Roth A; Khattra J; Ho J; Yap D; Prentice LM; Melnyk N; McPherson A; Bashashati A; Laks E; Biele J; Ding J; Le A; Rosner J; Shumansky K; Marra MA; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP
    Genome Res; 2014 Nov; 24(11):1881-93. PubMed ID: 25060187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
    Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
    Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
    Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
    Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-neoplastic Fallopian Tube Epithelium Carrying Gene Mutations of a Novel SOX2 Repressor Region is Soil of High-grade Serous Ovarian Cancer.
    Hirohashi Y; Torigoe T
    EBioMedicine; 2016 Aug; 10():17-8. PubMed ID: 27423191
    [No Abstract]   [Full Text] [Related]  

  • 30. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
    Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
    BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HMGA2 and high-grade serous ovarian carcinoma.
    Wu J; Wei JJ
    J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
    Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
    Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.
    Vollan HK; Rueda OM; Chin SF; Curtis C; Turashvili G; Shah S; Lingjærde OC; Yuan Y; Ng CK; Dunning MJ; Dicks E; Provenzano E; Sammut S; McKinney S; Ellis IO; Pinder S; Purushotham A; Murphy LC; Kristensen VN; ; Brenton JD; Pharoah PD; Børresen-Dale AL; Aparicio S; Caldas C
    Mol Oncol; 2015 Jan; 9(1):115-27. PubMed ID: 25169931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
    Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
    Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amplicon profiles in ovarian serous carcinomas.
    Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
    Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-grade serous ovarian cancer: the clone wars.
    Salomon-Perzyński A; Salomon-Perzyńska M; Michalski B; Skrzypulec-Plinta V
    Arch Gynecol Obstet; 2017 Mar; 295(3):569-576. PubMed ID: 28154920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational heterogeneity in non-serous ovarian cancers.
    Teer JK; Yoder S; Gjyshi A; Nicosia SV; Zhang C; Monteiro ANA
    Sci Rep; 2017 Aug; 7(1):9728. PubMed ID: 28852190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.
    Wong KK; Gershenson D
    Dis Markers; 2007; 23(5-6):377-87. PubMed ID: 18057521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.